PIK3CA and prostate cancer: A panel of PTEN null and PTEN WT prostate cancer cell lines were treated with increasing concentrations of docetaxel for 24 h and PI3K/AKT pathway activation analysed in the docetaxel-persister cells by immunoblotting (Fig. 2a, b).